Company Research Report: NeraCare

Company Overview

• Name: NeraCare

• Mission: Bring individualized treatment decisions to all patients diagnosed with skin cancer.

• Founded By: No information is available.

• Key People:

• Daniel von Janowski, Managing Director

• Dr. Matthias Ackermann, Managing Director

• Headquarters:

• NeraCare GmbH: Eschenheimer Anlage 26, 60318 Frankfurt, Germany

• NeraCare Inc.: 1209 Orange Street, Wilmington, DE 19801, USA

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Leading developer of laboratory tests for personalized survival prediction of melanoma patients.

Products

MELAGENIX

• Description: A quantitative RT-PCR assay based on the expression of eleven genes (eight prognostic and three reference genes) around primary melanoma tissue. It is primarily used to assist in individualized therapeutic decisions for stage II/III melanoma patients.

• Key Features:

• Allocates patients into two groups:

• Low score indicates a lower chance of cancer returning.

• High score indicates a higher chance of cancer returning.

• Clinical Validation: Proven as an independent prognostic factor in stage II cutaneous melanoma patients.

Immunoprint

• Description: An immunohistochemistry-based assay aimed at changing the treatment algorithm for patients diagnosed with early-stage melanoma.

• Key Features:

• 7-IHC risk categorization assay used to stratify early-stage (IB/IIA) cutaneous melanoma patients into high-risk or low-risk groups for recurrence and melanoma-specific survival.

• Identified 98% of relapses and 100% of deaths in stage IB/IIA patients.

• Used to identify high-risk early-stage melanoma patients for adjuvant trials.

Recent Developments

• New Partnerships:

• Akoya Biosciences Partnership (May 2024): Exclusive agreement to develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients.

• SkylineDx Dissolution (January 2024): NeraCare and SkylineDx dissolved their strategic partnership to proceed independently.

• SkylineDx Partnership (April 2023): Initially announced a strategic partnership focusing on Immunoprint® to improve individualized melanoma treatment.

• Clinical Trials:

• NivoMela Trial (Initiated in 2020): The first clinical trial in melanoma to select patients for adjuvant treatment based on individualized risk for relapse. The trial fully enrolled approximately 400 stage II patients.

• MELARISK-001 Study: Clinical validation of a prognostic 7-marker IHC assay in 382 patients with stage IB/IIA cutaneous melanoma.

• New Product Launches & Features:

• Automation and Tissue Preservation (May 2024): The 7-IHC assay is being transferred to Akoya Biosciences’ PhenoImager HT multiplex platform to enable automation and minimize tissue samples.

• Venture Capital Funding: Raised more than $20 million in financing led by MIG Capital AG, also a founding investor of BioNTech.

Contact Information

• Phone: +49 (69) 2731595-00

• Email: info@neracare.com

• Imprint: Copyright 2024 © All Rights reserved.